Bormioli Pharma, Chiesi Partner to Supply Carbon Capture PET Bottles

Bormioli Pharma, a pharmaceutical packaging provider, entered a partnership with Chiesi, an international, research-focused biopharmaceutical company, to supply Carbon Capture PET bottles. These will be used to package a medication indicated for the prophylaxis and treatment of seasonal and perennial allergic rhinitis, as well as vasomotor rhinitis.
 
This supply marks the first time a Carbon Capture PET bottle will be used for pharmaceutical purposes, offering environmental benefits and high safety levels for patients. Carbon Capture PET bottles provide a 21.9% decrease in kg of CO2 eq compared to traditional PET, while extractables’ levels are comparable with the ones registered by standard PET.
 
Carbon Capture PET is produced by capturing carbon emissions, which are then transformed into BioMEG, the key molecule for PET production, through a fermentation process.  The material is recyclable and maintains the same mechanical and physical performance as traditional PET.
 
“The agreement we’ve reached with Chiesi to supply one of their products with Carbon Capture PET bottles demonstrates both the performance and safety of these containers, as well as the growing commitment of the pharma industry towards sustainability,” said Andrea Lodetti, CEO of Bormioli Pharma. “As of today, almost half of our sales are made up of products manufactured with low-impact materials, thanks to the development of one of the widest sustainable packaging offerings available in the pharma industry, EcoPositive, which comprises over 3,000 items in glass or plastic.”